clinical trial · NCT02945020
A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants
Janssen Research & Development, LLC·phase1·completed·n = 15
HealthyDabigatran etexilate mesylateOdalasvir (ODV)Simeprevir (SMV)
brief summary
The purpose of this study is to evaluate the effect of steady-state concentrations of odalasvir (ODV), as a single agent or in combination with simeprevir (SMV), on the single-dose pharmacokinetics of dabigatran etexilate in healthy participants.
started
Nov 10, 2016
primary completion
Jan 9, 2017
completion
Jan 20, 2017
last updated
Feb 3, 2025
official title
A Phase 1, Open-label, Sequential Study to Investigate the Pharmacokinetic Interaction Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol